Merck’s cladribine tablet, Mavenclad achieves sustained control of relapsing multiple sclerosis.
And the death of a patient enrolled in a CART- study puts Cellectis’ work on an off-the-shelf CAR-T therapy on hold.
The Biotechnology Focus, Stratford Managers, and BioTalent Canada 2017 biotechnology employee survey has been extended to September 22.
These are the stories we have for you on the latest episode of the Biotechnology Focus podcast.
To read the stories in full, click on the links below: